Kane Biotech Strengthens Board with Biotech Executive
November 16 2023 - 1:45PM
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane
Biotech” or “Kane”) is pleased to announce that John Coleman has
been appointed to the Board of Directors of Kane Biotech effective
immediately.
Dr. Coleman brings a wealth of scientific and business expertise
to the board. Currently serving as the President and CEO of Avivo
Biomedical Inc., a Vancouver-based biotech firm specializing in
groundbreaking technologies facilitating the conversion of blood
and organs into universally accepted types, thereby significantly
improving the utilization of the existing pool of donors. Before
his tenure at Avivo, Coleman co-founded Anandia Labs in 2013,
growing it to become a leading cannabis testing and genetics
company. Following Anandia's acquisition by Aurora Cannabis in
2018, Coleman continued to lead analytical testing at Anandia until
2020.
Formerly, Dr. Coleman served as the Department Head for the
Project Search and Evaluation Division of the Centre for Drug
Research and Development (CDRD, now adMare) from 2007 to 2015. His
earlier experiences include diverse roles at Inflazyme
Pharmaceuticals Ltd., a Vancouver-based biotechnology company
specializing in treatments for respiratory and inflammatory
diseases and leading the natural products group at Ocean Nutrition
Canada in Halifax, Nova Scotia.
"I am thrilled to join Kane's Board of Directors as they
endeavor to bring transformative biofilm-targeted products to
patients. I look forward to contributing to Kane's ability to
execute on the Company's compelling vision," remarked Dr.
Coleman
“We are excited to have John’s energy, enthusiasm, and
perspective as Kane enters the next stage of its growth,” stated
Marc Edwards, CEO of Kane Biotech. “As a key addition to our Board,
John’s guidance will be essential as we continue to advance our
pipeline of potential first-in-class and best-in-class targeted
biofilm products.”
About John ColemanJohn Coleman holds a BSc.
(Honours) from Bishop’s University (1992) and a PhD from the
University of British Columbia (1997). He is currently the
President and CEO of Avivo Biomedical Inc.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms. The Company has a portfolio
of biotechnologies, intellectual property (80 patents and patents
pending, trade secrets and trademarks) and products developed by
the Company's own biofilm research expertise and acquired from
leading research institutions. StrixNB™, DispersinB®, Aledex™,
bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®,
DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane
Biotech Inc. The Company is listed on the TSX Venture Exchange
under the symbol "KNE" and on the OTCQB Venture Market under the
symbol “KNBIF”.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Caution Regarding Forward-Looking
InformationThis press release contains certain statements regarding
Kane Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect
management’s current beliefs and are based on information currently
available to management. Certain material factors or assumptions
are applied in making forward-looking statements, and actual
results may differ materially from those expressed or implied in
such statements. These risks and uncertainties include, but are not
limited to, risks relating to the Company’s: (a) financial
condition, including lack of significant revenues to date and
reliance on equity and other financing; (b) business, including its
early stage of development, government regulation, market
acceptance for its products, rapid technological change and
dependence on key personnel; (c) intellectual property including
the ability of the Company to protect its intellectual property and
dependence on its strategic partners; and (d) capital structure,
including its lack of dividends on its common shares, volatility of
the market price of its common shares and public company costs.
Further information about these and other risks and uncertainties
can be found in the disclosure documents filed by the Company with
applicable securities regulatory authorities, available
at www.sedar.com. The Company cautions that the foregoing list
of factors that may affect future results is
not exhaustive.
Marc Edwards
Chief Executive Officer
Kane Biotech Inc
medwards@kanebiotech.com
Ray Dupuis
Chief Financial Officer
Kane Biotech Inc
rdupuis@kanebiotech.com
Nicole Sendey
Investor Relations/PR
Kane Biotech Inc
nsendey@kanebiotech.com
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Aug 2023 to Aug 2024